OPX 212Alternative Names: OPX-212
Latest Information Update: 14 Nov 2015
At a glance
- Originator Opexa Therapeutics
- Class Anti-inflammatories; Cell therapies; Eye disorder therapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neuromyelitis optica